NASDAQ:PZRX - PhaseRx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2806 0.00 (0.00 %)
(As of 07/16/2018 03:17 PM ET)
Previous Close$0.2806
Today's RangeN/A
52-Week Range$0.22 - $1.95
Average Volume1.24 million shs
Market Capitalization$268,881.00
P/E RatioN/A
Dividend YieldN/A
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Receive PZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PZRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A


Debt-to-Equity Ratio-12.03
Current Ratio2.14
Quick Ratio2.14


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$370,000.00
Price / Sales8.87
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book0.36


EPS (Most Recent Fiscal Year)N/A
Net Income$-20,130,000.00
Net MarginsN/A
Return on Equity-332.32%
Return on Assets-124.69%


Outstanding Shares11,690,000
Market Cap$0.27

The Truth About Cryptocurrencies

PhaseRx (NASDAQ:PZRX) Frequently Asked Questions

What is PhaseRx's stock symbol?

PhaseRx trades on the NASDAQ under the ticker symbol "PZRX."

How were PhaseRx's earnings last quarter?

PhaseRx Inc (NASDAQ:PZRX) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.14. View PhaseRx's Earnings History.

What is the consensus analysts' recommendation for PhaseRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseRx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are PhaseRx's key executives?

PhaseRx's management team includes the folowing people:
  • Steven H. Gillis Ph.D., Independent Chairman of the Board (Age 63)
  • Robert W. Overell Ph.D., President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director (Age 61)
  • Sean Monahan Ph.D., Vice President - Chemistry
  • Mary G. Prieve Ph.D., Vice President - Biology
  • Gordon Brandt M.D., Chief Medical Officer (Age 57)
  • James D. Watson, Head of Corporate Development
  • Paul H. Johnson Ph.D., Director (Age 73)
  • Brian G. Atwood, Independent Director (Age 64)
  • Michelle Renee Griffin, Independent Director (Age 51)
  • Peggy V. Phillips, Independent Director (Age 63)

When did PhaseRx IPO?

(PZRX) raised $18 million in an initial public offering on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners served as the underwriters for the IPO.

Has PhaseRx been receiving favorable news coverage?

News stories about PZRX stock have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PhaseRx earned a news impact score of 0.05 on Accern's scale. They also gave news articles about the company an impact score of 45.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of PhaseRx?

Shares of PZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PhaseRx's stock price today?

One share of PZRX stock can currently be purchased for approximately $0.2806.

How big of a company is PhaseRx?

PhaseRx has a market capitalization of $268,881.00 and generates $370,000.00 in revenue each year. PhaseRx employs 21 workers across the globe.

How can I contact PhaseRx?

PhaseRx's mailing address is 410 W Harrison St Ste 300, SEATTLE, WA 98119-4034, United States. The company can be reached via phone at +1-206-8056300 or via email at [email protected]

MarketBeat Community Rating for PhaseRx (NASDAQ PZRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about PhaseRx and other stocks. Vote "Outperform" if you believe PZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.